415 related articles for article (PubMed ID: 33344042)
21. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
22. Macrophage migration inhibitory factor promotes the migration of dendritic cells through CD74 and the activation of the Src/PI3K/myosin II pathway.
Ives A; Le Roy D; Théroude C; Bernhagen J; Roger T; Calandra T
FASEB J; 2021 May; 35(5):e21418. PubMed ID: 33774873
[TBL] [Abstract][Full Text] [Related]
23. Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4.
Krijgsman O; Kemper K; Boshuizen J; Vredevoogd DW; Rozeman EA; Ibanez Molero S; de Bruijn B; Cornelissen-Steijger P; Shahrabi A; Del Castillo Velasco-Herrera M; Song JY; Ligtenberg MA; Kluin RJC; Kuilman T; Ross-Macdonald P; Haanen JBAG; Adams DJ; Blank CU; Peeper DS
Clin Cancer Res; 2021 Oct; 27(19):5389-5400. PubMed ID: 34230026
[TBL] [Abstract][Full Text] [Related]
24. Acidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patients.
Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; Habash M; Sheppard AD; MacLean M; Dunne MR; Moore J; Temperley H; Conroy MJ; Butler C; Bhardwaj A; Ravi N; Donohoe CL; Reynolds JV; Lysaght J
Cancer Immunol Immunother; 2023 Jan; 72(1):55-71. PubMed ID: 35708739
[TBL] [Abstract][Full Text] [Related]
25. The Abscopal Effect in the Era of Checkpoint Inhibitors.
Kodet O; Němejcova K; Strnadová K; Havlínová A; Dundr P; Krajsová I; Štork J; Smetana K; Lacina L
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281259
[TBL] [Abstract][Full Text] [Related]
26. Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles.
Mahdavi Gorabi A; Sadat Ravari M; Sanaei MJ; Davaran S; Kesharwani P; Sahebkar A
Int Immunopharmacol; 2022 Dec; 113(Pt A):109300. PubMed ID: 36252486
[TBL] [Abstract][Full Text] [Related]
27. The Role of Immune Checkpoint Blockade in Uveal Melanoma.
Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269
[TBL] [Abstract][Full Text] [Related]
28. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
Grasso CS; Tsoi J; Onyshchenko M; Abril-Rodriguez G; Ross-Macdonald P; Wind-Rotolo M; Champhekar A; Medina E; Torrejon DY; Shin DS; Tran P; Kim YJ; Puig-Saus C; Campbell K; Vega-Crespo A; Quist M; Martignier C; Luke JJ; Wolchok JD; Johnson DB; Chmielowski B; Hodi FS; Bhatia S; Sharfman W; Urba WJ; Slingluff CL; Diab A; Haanen JBAG; Algarra SM; Pardoll DM; Anagnostou V; Topalian SL; Velculescu VE; Speiser DE; Kalbasi A; Ribas A
Cancer Cell; 2020 Oct; 38(4):500-515.e3. PubMed ID: 32916126
[TBL] [Abstract][Full Text] [Related]
29. Chemokines mRNA expression in relation to the Macrophage Migration Inhibitory Factor (MIF) mRNA and Vascular Endothelial Growth Factor (VEGF) mRNA expression in the microenvironment of endometrial cancer tissue and normal endometrium: a pilot study.
Giannice R; Erreni M; Allavena P; Buscaglia M; Tozzi R
Cytokine; 2013 Nov; 64(2):509-15. PubMed ID: 23985752
[TBL] [Abstract][Full Text] [Related]
30. Macrophage migration inhibitory factor counterregulates dexamethasone-mediated suppression of hypoxia-inducible factor-1 alpha function and differentially influences human CD4+ T cell proliferation under hypoxia.
Gaber T; Schellmann S; Erekul KB; Fangradt M; Tykwinska K; Hahne M; Maschmeyer P; Wagegg M; Stahn C; Kolar P; Dziurla R; Löhning M; Burmester GR; Buttgereit F
J Immunol; 2011 Jan; 186(2):764-74. PubMed ID: 21169549
[TBL] [Abstract][Full Text] [Related]
31. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulatory Protective Effects of Rb9 Cyclic-Peptide in a Metastatic Melanoma Setting and the Involvement of Dendritic Cells.
Machado FC; Girola N; Maia VSC; Bergami-Santos PC; Morais AS; Azevedo RA; Figueiredo CR; Barbuto JAM; Travassos LR
Front Immunol; 2019; 10():3122. PubMed ID: 32010152
[TBL] [Abstract][Full Text] [Related]
33. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
[TBL] [Abstract][Full Text] [Related]
34. Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade.
Gambichler T; Strutzmann S; Tannapfel A; Susok L
BMC Cancer; 2017 May; 17(1):327. PubMed ID: 28499411
[TBL] [Abstract][Full Text] [Related]
35. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
36. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
[TBL] [Abstract][Full Text] [Related]
37. BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti-CTLA-4 treatment.
Tseng HY; Alavi S; Gallagher S; McGuire HM; Hersey P; Al Emran A; Tiffen J
Pigment Cell Melanoma Res; 2024 May; ():. PubMed ID: 38725219
[TBL] [Abstract][Full Text] [Related]
38. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
39. Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4
Mastracci L; Fontana V; Queirolo P; Carosio R; Grillo F; Morabito A; Banelli B; Tanda E; Boutros A; Dozin B; Gualco M; Salvi S; Romani M; Spagnolo F; Poggi A; Pistillo MP
Cancer Immunol Immunother; 2020 Apr; 69(4):653-662. PubMed ID: 32025849
[TBL] [Abstract][Full Text] [Related]
40. Targeting WEE1/AKT Restores p53-Dependent Natural Killer-Cell Activation to Induce Immune Checkpoint Blockade Responses in "Cold" Melanoma.
Dinavahi SS; Chen YC; Punnath K; Berg A; Herlyn M; Foroutan M; Huntington ND; Robertson GP
Cancer Immunol Res; 2022 Jun; 10(6):757-769. PubMed ID: 35439317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
